Performance-Driven Payments in Europe
Payment of high-priced drugs in the UK, BeNeLuxAI, Italy and Germany
- Reimbursement models in the UK for highly specialised technologies
- BeNeLuxAI - HTA and pricing coordination
- Performance-driven payments in Germany through the GSAV?
- Adapting risk-sharing schemes for ATMPs in Italy?
Aims and objectivesThe German draft drug law GSAV foresees registries for orphan drugs; first performance-driven payment contracts have already been established. Other countries, such as Italy, have used this pricing model for quite some time.
This conference compiles Europe's various tendencies in regard to the payment of high-priced innovative drugs, which are about to enter the European market.
After attending this meeting, you will be aware of the existing payment models and be knowledgeable about the upcoming payment trends in Europe. Lastly, you will get to know possibilities you have in the direct contraction situation with payers.
Those involved in value-assessment preparation and pricing activities will benefit particularly from this conference.
(from 09:00 registration)
- Outcomes of the ORPH-VAL report
- Pricing and reimbursement models for rare diseases in France, Spain and throughout Europe
- Evaluating medicines and technologies for rare and ultra-rare conditions
- Impact of registries on HTA and further payer cooperation
10:30 Coffee break
- HTA and pricing coordination
- Which products are likely to be subject to mandatory G-BA registries?
- When to engage with G-BA?
- AIFA registries and managed entry agreements
- Legal framework on MEAs
- Stakeholders' involvement: AIFA, regions, hospitals, pharmacies and pharmaceutical companies
- Adapting risk-sharing schemes for ATMPs?
15:00 Coffee break
- Deferred payments vs. payback guarantee: pros and cons
- Impact on AMNOG and early access
- Where does payer and company interest differ?
- Gene therapy and the need for alignment on registration design
- How to apply for hospital treatments
17:00 End of conference
Since 2009, Alexander Natz is Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as lawyer in his own law firm in Düsseldorf (www.natz-law.com). From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer with Sträter Law Firm in Germany with a special focus on discount agreements and licensing of pharmaceuticals. Dr. Natz also was working in the field of competition law with the European Commission and the pharmaceutical industry. As research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling.
VP, Head of Market Access EMEA
Advisor to the Ministry of Health and Social Affairs
Associate Director Highly Specialised Technologies
Pharmaceutical Scientific Advisor, Research consultant at UCSC with tasks on EUnetHTA JA3 WP5 and HTA WP6 & WP10, from 2013 - 2016: AIFA’s Registries Co-ordinator
Phone: +49 30 200 767 0
Fax: +49 30 200 767 599
- Discussions with experts from HTA agencies and industry
- Focus on the UK, BeNeLuXAI, Italy and Germany
- Talks on gene therapy, orphan drugs and other high-priced drugs